The Influence of CYP2C19 Genetic Polymorphism on the Pharmacokinetics/-Pharmacodynamics of Proton Pump Inhibitor-Containing Helicobacter pylori Treatments

被引：25
作者：
Serrano, Dolores [1 ]
Torrado, Susana [1 ]
Torrado-Santiago, Santiago [1 ]
Gisbert, Javier P. [2 ]
机构：
[1] Univ Complutense, Fac Farm, Dept Pharmaceut Technol, E-28040 Madrid, Spain
[2] Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IP, Dept Gastroenterol, Madrid, Spain
来源：
CURRENT DRUG METABOLISM | 2012年 / 13卷 / 09期
关键词：
CYP2C19; genetic polymorphism; Helicobacter pylori eradication; proton pump inhibitor; rabeprazole; omeprazole; lansoprazole; pantoprazole; esomeprazole; CYTOCHROME-P450; ENZYMES; 2C9; 1-WEEK TRIPLE THERAPY; RANDOMIZED OPEN TRIAL; ERADICATION RATE; CURE RATES; OMEPRAZOLE METABOLISM; GENOTYPIC DIFFERENCES; DRUG-METABOLISM; DUAL THERAPY; RABEPRAZOLE;
D O I：
10.2174/138920012803341393
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Proton pump inhibitors (PPIs) are the most potent acid suppressants available. PPIs undergo hepatic metabolism via the CYP2C system for the isoforms CYP2C19 and CYP3A4 in particular. Genetic polymorphisms in CYP2C19 may affect the metabolism of individual PPIs to different extents. Although PPIs are highly effective as a class, differences in their pharmacokinetics, such as bioavailability and metabolism, may translate into differences in clinical outcomes. In Helicobacter pylori infection, a significantly lower eradication rate was seen in extensive metabolizers with omeprazole but no with rabeprazole.
引用
收藏
页码：1303 / 1312
页数：10
相关论文
共 50 条
  • [31] Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin
    Oh, Jung-Hwan
    Dong, Mi-Sook
    Choi, Myung-Gyu
    Yoo, Hae-Won
    Lee, Sang-Bum
    Park, Young In
    Chung, In-Sik
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 (02) : 294 - 298
  • [32] CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication
    Tsung-Jung Lin
    Hsi-Chang Lee
    Chih-Lin Lin
    Chung-Kwe Wang
    Kuan-Yang Chen
    Deng-Chyang Wu
    World Journal of Clinical Cases, 2018, 6 (12) : 514 - 520
  • [33] Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy
    Sugimoto, Mitsushige
    Hira, Daiki
    Murata, Masaki
    Kawai, Takashi
    Terada, Tomohiro
    ANTIBIOTICS-BASEL, 2020, 9 (10): : 1 - 11
  • [34] Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects
    Katsuki, H
    Nakamura, C
    Arimori, K
    Fujiyama, S
    Nakano, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (05) : 391 - 396
  • [35] Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite
    Boulenc, Xavier
    Djebli, Nassim
    Shi, Juan
    Perrin, Laurent
    Brian, William
    Van Horn, Robert
    Hurbin, Fabrice
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (01) : 187 - 197
  • [36] Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors
    Kita, T
    Sakaeda, T
    Baba, T
    Aoyama, N
    Kakumoto, M
    Kurimoto, Y
    Kawahara, Y
    Okamura, N
    Kirita, S
    Kasuga, M
    Okumura, K
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2003, 26 (03) : 386 - 390
  • [37] Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs
    Lima, John J.
    Franciosi, James P.
    PHARMACOGENOMICS, 2014, 15 (11) : 1405 - 1416
  • [38] CYP2C19 genetic polymorphism in the Vietnamese population
    Nhung Phuong Vu
    Hoa Thi Thanh Nguyen
    Ngoc Thi Bich Tran
    Ton Dang Nguyen
    Hue Thi Thu Huynh
    Xuan Thi Nguyen
    Duong Thuy Nguyen
    Hai Van Nong
    Ha Hai Nguyen
    ANNALS OF HUMAN BIOLOGY, 2019, 46 (06) : 491 - 497
  • [39] Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis
    Ichikawa, Hitomi
    Sugimoto, Mitsushige
    Sugimoto, Ken
    Andoh, Akira
    Furuta, Takahisa
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (04) : 716 - 726
  • [40] Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects
    Cho, Chang-Keun
    Byeon, Ji-Young
    Kang, Pureum
    Park, Hye-Jung
    Ko, Eunvin
    Mu, Chou Yen
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (02) : 111 - 116
12345